中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 1
Jan.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(1): 160-166

Changing trend of benign hepatobiliary and pancreatic diseases among people aged 15—39 years in China in 1990—2021

DOI: 10.12449/JCH260119
  • 1.

    Department of General Surgery，The First Affiliated Hospital of Xi’an Medical University，Xi’an 710077，China

  • 2.

    The Second Clinical Medical School of Lanzhou University，Lanzhou 730030，China

  • 3.

    Gansu Engineering Research Center for Precision Diagnosis and Treatment of Hepatobiliary and Pancreatic Diseases，Lanzhou 730030，China

Research funding:

National College Student Innovation and Entrepreneurship Training Program (20250050119);

Gansu Provincial Natural Science Foundation (25JRRA627);

Cuiying Scientific Training Program for Undergraduates of the Second Hospital & Clinical Medical School of Lanzhou University (CYXZSC2025-07)

More Information
  • Corresponding author: TIAN Ming， smztian@163.com （ORCID： 0009-0005-7675-0283）
  • Received Date: 2025-08-22
  • Accepted Date: 2025-10-14
  • Published Date: 2026-01-25
    Abstract
  •   Objective  To investigate the changing trends of the incidence rate， prevalence rate， mortality rate， and disability-adjusted life years （DALYs） of benign hepatobiliary and pancreatic diseases among people aged 15 — 39 years in China in 1990 — 2021.  Methods  The data of 2021 Global Burden of Disease Study were downloaded to obtain the epidemiological data of liver fibrosis/chronic liver disease， benign gallbladder/biliary tract diseases， and pancreatitis among people aged 15 — 39 years in China， and estimated annual percentage change （EAPC） was calculated to assess the changing trends of incidence， prevalence， mortality， and DALY rates. The Bayesian age-period-cohort model was used to predict the incidence and mortality rates from 2022 to 2030.  Results  In 2021， there were 10 448 778 new cases of benign hepatobiliary and pancreatic diseases among the individuals aged 15 — 39 years in China， which was increased by 3.8% compared with the data in 1990， while the numbers of prevalent cases， deaths， and DALYs were reduced by 20.4%， 59.6%， and 50.2%， respectively. In 2021， the age-standardized incidence rates of liver fibrosis/chronic liver disease， benign gallbladder/biliary tract diseases， and pancreatitis were 1 104.40/100 000， 1 045.05/100 000， and 16.64/100 000， respectively； the age-standardized prevalence rates were 20 592.37/100 000， 2 364.85/100 000， and 9.43/100 000， respectively； the age-standardized mortality rates were 1.61/100 000， 0.04/100 000， and 0.18/100 000， respectively. From 1990 to 2021， there was a tendency of increase in the age-standardized incidence rate of liver fibrosis/chronic liver disease （EAPC=0.43， 95% confidence interval ［CI］： 0.23 — 0.63）， and there was also a tendency of increase in the age-standardized incidence and prevalence rates of benign gallbladder/biliary tract diseases （incidence rate： EAPC=1.07， 95%CI： 0.91 — 1.24； prevalence rate： EAPC=0.75， 95%CI： 0.59 — 0.89）， while there was a tendency of reduction in the age-standardized mortality rate of all three disease categories. Predictions for 2022 — 2030 indicated a potential reduction in the incidence rate of benign gallbladder/biliary tract diseases and an increase in the incidence rate of pancreatitis.  Conclusion  There has been an overall upward trend in the incidence rate of liver fibrosis/chronic liver disease and gallbladder/biliary tract diseases over the past three decades， and it is needed to pay attention to the disease burden of benign hepatobiliary diseases among the people aged 15 — 39 years in China.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    MURRAY CJL. The global burden of disease study at 30 years[J]. Nat Med, 2022, 28( 10): 2019- 2026. DOI: 10.1038/s41591-022-01990-1.
    [2]
    GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability(YLDs), disability-adjusted life-years(DALYs), and healthy life expectancy(HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2024, 403( 10440): 2133- 2161. DOI: 10.1016/S0140-6736(24)00757-8.
    [3]
    THAM EKJ, TAN DJH, DANPANICHKUL P, et al. The global burden of cirrhosis and other chronic liver diseases in 2021[J]. Liver Int, 2025, 45( 3): e70001. DOI: 10.1111/liv.70001.
    [4]
    DAI FY, CAI YZ, YANG SJ, et al. Global burden of gallbladder and biliary diseases(1990-2021) with healthcare workforce analysis and projections to 2035[J]. BMC Gastroenterol, 2025, 25( 1): 249. DOI: 10.1186/s12876-025-03842-x.
    [5]
    JIANG WK, DU Y, XIANG CF, et al. Age-period-cohort analysis of pancreatitis epidemiological trends from 1990 to 2019 and forecasts for 2044: A systematic analysis from the Global Burden of Disease Study 2019[J]. Front Public Health, 2023, 11: 1118888. DOI: 10.3389/fpubh.2023.1118888.
    [6]
    CHEN X, ZHANG LY, CHEN W. Global, regional, and national burdens of type 1 and type 2 diabetes mellitus in adolescents from 1990 to 2021, with forecasts to 2030: A systematic analysis of the global burden of disease study 2021[J]. BMC Med, 2025, 23( 1): 48. DOI: 10.1186/s12916-025-03890-w.
    [7]
    LUO ZY, SHAN SY, CAO J, et al. Temporal trends in cross-country inequalities of stroke and subtypes burden from 1990 to 2021: A secondary analysis of the global burden of disease study 2021[J]. E Clinical Medicine, 2024, 76: 102829. DOI: 10.1016/j.eclinm.2024.102829.
    [8]
    DENG YJ, WEI BJ, ZHAI Z, et al. Dietary risk-related colorectal cancer burden: Estimates from 1990 to 2019[J]. Front Nutr, 2021, 8: 690663. DOI: 10.3389/fnut.2021.690663.
    [9]
    LI TY, ZHANG HX, LIAN MY, et al. Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021[J]. J Hematol Oncol, 2025, 18( 1): 5. DOI: 10.1186/s13045-025-01660-y.
    [10]
    YUAN QH, WANG LJ, SUN BJ, et al. Global, regional, and national differences in the burden of refraction disorders among children, adolescents, and older adults: Current trends and future projections[J]. BMC Public Health, 2025, 25( 1): 2653. DOI: 10.1186/s12889-025-23887-7.
    [11]
    WANG YF, LU HL, HU MR, et al. Alcohol consumption in China before and during COVID-19: Preliminary results from an online retrospective survey[J]. Front Psychiatry, 2020, 11: 597826. DOI: 10.3389/fpsyt.2020.597826.
    [12]
    YUE TT, ZHANG QQ, CAI T, et al. Trends in the disease burden of HBV and HCV infection in China from 1990-2019[J]. Int J Infect Dis, 2022, 122: 476- 485. DOI: 10.1016/j.ijid.2022.06.017.
    [13]
    ZHUANG Q, DONG ZX, WAN XJ. Research progress of effect of estrogen and its receptors on cholesterol gallstone disease[J]. J Shanghai Jiao Tong Univ Med Sci, 2021, 41( 10): 1394- 1396. DOI: 10.3969/j.issn.1674-8115.2021.10.020.

    庄谦, 董志霞, 宛新建. 雌激素及其受体影响胆固醇结石形成的研究进展[J]. 上海交通大学学报(医学版), 2021, 41( 10): 1394- 1396. DOI: 10.3969/j.issn.1674-8115.2021.10.020.
    [14]
    JIANG MK, LU ZQ, ZHOU WM, et al. Analysis of the disease burden of pancreatitis in China from 1990 to 2019[J]. Chin J Evid Based Med, 2022, 22( 8): 869- 875.

    蒋梦可, 陆宗庆, 周伍明, 等. 1990—2019年中国胰腺炎疾病负担分析[J]. 中国循证医学杂志, 2022, 22( 8): 869- 875.
    [15]
    QI Y, YAN Q, SUN LJ, et al. Trends of smoking and drinking behaviors among adolescents in Shanghai from 2004 to 2019[J]. Chin J Sch Health, 2022, 43( 7): 1003- 1006, 1010. DOI: 10.16835/j.cnki.1000-9817.2022.07.011.

    祁月, 严琼, 孙力菁, 等. 上海市2004—2019年青少年吸烟饮酒行为变化趋势[J]. 中国学校卫生, 2022, 43( 7): 1003- 1006, 1010. DOI: 10.16835/j.cnki.1000-9817.2022.07.011.
    [16]
    QU YB, SHEN SJ, YUAN HH, et al. Trends of substance abuse behavior among adolescents in Guangdong Province, 2007-2016[J]. Chin J Sch Health, 2020, 41( 11): 1650- 1653. DOI: 10.16835/j.cnki.1000-9817.2020.11.014.

    曲亚斌, 沈少君, 袁华晖, 等. 广东省2007—2016年青少年物质滥用行为变化趋势[J]. 中国学校卫生, 2020, 41( 11): 1650- 1653. DOI: 10.16835/j.cnki.1000-9817.2020.11.014.
    [17]
    PAIK JM, KABBARA K, EBERLY KE, et al. Global burden of NAFLD and chronic liver disease among adolescents and young adults[J]. Hepatology, 2022, 75( 5): 1204- 1217. DOI: 10.1002/hep.32228.
    [18]
    ZHAO ZH, WEI TH, QIAN NN, et al. Disease burden of cirrhosis caused by non-alcoholic fatty liver disease in China, 1990-2021: a comparative analysis with global trends[J]. Chin J Dis Control Prev, 2025, 29( 7): 782- 789. DOI: 10.16462/j.cnki.zhjbkz.2025.07.006.

    赵自豪, 魏涛华, 钱南南, 等. 1990―2021年中国非酒精性脂肪性肝病疾病负担:与全球的对比分析[J]. 中华疾病控制杂志, 2025, 29( 7): 782- 789. DOI: 10.16462/j.cnki.zhjbkz.2025.07.006.
    [19]
    PAN XF, WANG LM, PAN A. Epidemiology and determinants of obesity in China[J]. Lancet Diabetes Endocrinol, 2021, 9( 6): 373- 392. DOI: 10.1016/S2213-8587(21)00045-0.
    [20]
    CHEN XT, WEN XS, ZHANG Y, et al. 7-year longitudinal prevalence of nonalcoholic fatty liver disease in children and adolescents in Shanghai Minhang District: A cross-sectional survey from 2014 to 2020[J]. Chin J Evid Based Pediatr, 2022, 17( 2): 109- 115. DOI: 10.3969/j.issn.1673-5501.2022.02.005.

    陈逍天, 温晓飒, 张羿, 等. 上海市闵行区儿童青少年非酒精性脂肪肝病7年患病率横断面调查[J]. 中国循证儿科杂志, 2022, 17( 2): 109- 115. DOI: 10.3969/j.issn.1673-5501.2022.02.005.
    [21]
    WANG K, LIU ZG, TANG RM, et al. Gallstones in the era of metabolic syndrome: Pathophysiology, risk prediction, and management[J]. Cureus, 2025, 17( 3): e80541. DOI: 10.7759/cureus.80541.
    [22]
    ALIMUJIANG YMT TEK, MA YF, LI CY, et al. Growth and development of Chinese adolescents and the trend of overweight[J/OL]. Acta Anthropol Sin, 2025: 1- 11.( 2025-04-23). https://link.cnki.net/doi/10.16359/j.1000-3193/AAS.2025.0020. DOI: 10.16359/j.1000-3193/AAS.2025.0020

    阿力木江·依米提·塔尔肯, 马云飞, 李成跃, 等. 中国青少年的生长发育及超重趋势[J/OL]. 人类学学报, 2025: 1- 11.( 2025-04-23). https://link.cnki.net/doi/10.16359/j.1000-3193/AAS.2025.0020. DOI: 10.16359/j.1000-3193/AAS.2025.0020
    [23]
    YANG JT, DENG SW, ZHAO HY, et al. The burden of type 2 diabetes in adolescents and young adults in China: A secondary analysis from the global burden of disease study 2021[J]. Health Data Sci, 2024, 4: 0210. DOI: 10.34133/hds.0210.
    [24]
    BEYER G, HABTEZION A, WERNER J, et al. Chronic pancreatitis[J]. Lancet, 2020, 396( 10249): 499- 512. DOI: 10.1016/S0140-6736(20)31318-0.
    [25]
    HU LH, JIN ZD. Advances in the diagnosis and treatment of dyspepsia in chronic pancreatitis patients[J]. J Clin Hepatol, 2023, 39( 12): 2757- 2762. DOI: 10.3969/j.issn.1001-5256.2023.12.002.

    胡良皞, 金震东. 慢性胰腺炎患者消化不良的诊治进展[J]. 临床肝胆病杂志, 2023, 39( 12): 2757- 2762. DOI: 10.3969/j.issn.1001-5256.2023.12.002.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (98) PDF downloads(38) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return